TABLE 4:

Statistically significant lowest cutoff rCBVT values tested for different mean differences

ParameterCutoff rCBVT Values
For Grading*For Differentiation
3.9a2.6b4.3c2.3d3.9e2.3f3.9g3.9h2.2i2.3j3.9k3.9l2.3m2.2n2.5o
ROC area0.9361.0000.9170.8040.9180.9290.9080.9410.9210.9350.9410.8960.8750.8670.875
SE0.0370.0000.0680.0610.0530.0470.0600.0490.0650.0520.0520.0690.0720.0850.079
AS0.0000.0000.0030.0000.0000.0000.0000.0010.0000.0000.0070.0000.0000.0040.001
Sensitivity95.4610010094.1290.9194.1295.4610094.1294.1210090.9183.3383.3375.00
Specificity91.6710083.3366.6788.2466.6788.2488.2490.0092.8688.2488.2491.6790.00100
PPV87.5010077.7857.1490.9157.1491.3077.7894.1294.1266.6783.3383.3390.91100
NPV97.0610010096.0088.2496.0093.7510090.0092.8610093.7591.6781.8282.35
Accuracy93.1010089.4775.4789.7475.4792.3191.6792.5993.5590.4889.2988.8986.3688.46
  • Note.—rCBVT indicates tumoral relative cerebral blood volume; ROC, area under curve; SE, standard error; AS, asymptotic significance; PPV, positive predictive value; NPV, negative predictive value.

  • * Superscripts indicate:

  • a Low- and high-grade glial tumors;

  • b low- and high-grade astrocytic gliomas;

  • c low- and high-grade non-astrocytic gliomas.

  • Superscripts indicate:

  • d Low-grade glial tumors from metastases

  • e high-grade glial tumors from metastases;

  • f low-grade astrocytomas from metastases;

  • g high-grade astrocytomas from metastases;

  • h high-grade non-astrocytic gliomas from metastases;

  • i pilocytic astrocytomas from metastases;

  • j diffuse astrocytomas from metastases;

  • k anaplastic astrocytomas from metastases;

  • l glioblastoma multiforme from metastases;

  • m low-grade astrocytomas from low-grade oligodendrogliomas;

  • n pilocytic astrocytomas from low-grade oligodendrogliomas;

  • o diffuse astrocytomas from low-grade oligodendrogliomas.